Tvardi Therapeutics announced its Q3 2026 financial results, reporting a net loss of $6.1 million and increased R&D expenses driven by clinical costs for its cancer drug TTI-101. The company is progressing its oral STAT3 inhibitors, preparing to start clinical trials for TTI-109 in ulcerative colitis pending IND clearance and funding, and expects topline data for TTI-101 in liver cancer in early 2027. These developments highlight Tvardi's focus on novel treatments for inflammatory and proliferative diseases, with potential significant impacts if trials succeed.
Tvardi Therapeutics' Q3 2026 results provide context for readers following health sector developments. As of Nov 13, 2026 18:41 WIB, among 150 priced US health-sector stocks tradable on Pluang, 93 rose and 49 fell. Notable movers include ASND at USD 274.96 with a 1-day change of +2.95%, BNGO at USD 1.01 down 2.88%, and RPRX at USD 67.09 down 2.73%.
KeyBanc lowered its price target for YETI Holdings to $49, suggesting a 27.94% upside from the current $38.30 stock price. This follows YETI's reduction of its full-year adjusted sales growth forecast to about 6% from the previous 7-8%, citing consum...
Bernstein SocGen Group has reduced its price target for Applied Materials to $600, even though the company reported higher sales and profits in Q4 2026 driven by strong demand for semiconductor services, especially AI chips. Applied Materials posted ...
Boralex Inc. announced a private placement of $600 million Canadian dollars in green bonds, split into two series maturing in 2031 and 2036 with interest rates of 4.503% and 5.173%, respectively. This marks Boralex's first issuance of green corporate...
Boralex Inc. announced the issuance of C$600 million in green bonds, split into two series with maturities in 2031 and 2036, bearing interest rates of 4.503% and 5.173% respectively. This marks Boralex's first green-labelled corporate securities offe...
Investec Bank Plc, acting as an exempt principal trader and advisor to DBAY Advisors Limited, disclosed the sale of 25,000 ordinary shares of Logistics Development Group Plc on November 12, 2026. The shares were sold at a price of 23 per unit. There ...
